SEC Form 4 filed by Director Carter Bruce L A

$ENTA
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $ENTA alert in real time by email

Weekly insight reads limit reached.

Join Quantisnow to enjoy unlimited reads, alerts, live feeds, and more.

Meet Quantisnow

Stock alerts. Live news feeds. Press releases. Insider trading. FDA approvals & more.

Invest smarter

A better trading workflow

Access market-moving news before they break out to the general public. Let Quantisnow cut out the noise and only receive insights that matter.

Live feeds
Real-time news feeds for Press Releases, SEC Filings, FDA approvals, market insights and more.
Custom filters
Filter out the noise with company filters, market cap filters, price filters and more.
Audio Squawk
Multitask with confidence and let Quantsinow read breaking news out loud.
Product screenshot
Quantisnow AI Features

Save time

Unlock Insights with AI

Get quick summaries and precise Q&A for every insight, empowering you to make informed decisions without sifting through entire press releases and lengthy SEC filings.

Get alerted immediately

All your stock market alerts in one place

Quantisnow alerts are fast, customizable, and versatile.

Email alerts
Subscribe to your favorite stocks and receive email alerts each time a news pops up.
App notifications
Reduce alerting latency with in-app notifications. Same as email alerts, but faster.
Webhooks
Integrate with Quantisnow programmatically and receive live insights via webhooks
Granular alerts
Want to receive Press Releases but no SEC filings? No problem - Quantisnow alerts are highly customizable and can seemlessly tailor to your trading needs.

Elevate your trading.
Start using Quantisnow today.

Never miss an update.

App screenshot

Simple no-tricks pricing

One membership with full access and no delays.

Quantisnow Plus

Your personal trading assistant for just $39/month.

What's included

  • Live feeds
  • Audio squawk
  • Compact mode in feeds
  • Email alerts
  • App push alerts
  • Unlimited insights reads
  • Unlimited subscriptions
  • Advanced filters in live feeds
  • Support
  • No ads
  • AI-generated summaries and Q&A

One membership - all access

$39/month

Get access

$39/month with yearly billing, $49/month with monthly billing

News insights ingested and delivered in real time
5 million+
Real-time news alerts sent out to Quantisnow users
700,000+
Latency of news delivery pipelines to users via mobile app, webhooks, and email
<100ms
Get the next $ENTA alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ENTA

DatePrice TargetRatingAnalyst
8/9/2023$14.00Neutral → Underweight
JP Morgan
8/8/2023$49.00 → $18.00Buy → Hold
Jefferies
12/9/2022$56.00Buy
H.C. Wainwright
7/6/2022$62.00In-line → Outperform
Evercore ISI
6/1/2022$39.00Underperform → In-line
Evercore ISI
2/9/2022$80.00 → $68.00Market Perform
SVB Leerink
1/13/2022$85.00 → $80.00Market Perform
SVB Leerink
11/24/2021$55.00 → $73.00Perform
Oppenheimer
More analyst ratings

$ENTA
Press Releases

Fastest customizable press release news feed in the world

See more
  • Enanta Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

    Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that members of management will present at the at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference on Thursday, March 27, 2025 at 11:00 a.m. ET. A live webcast of the event will be accessible by visiting the "Events and Presentations" section on the "Investors" page of Enanta's website at www.enanta.com. A replay of the webcast will be available following the presentation and will be archived for at least 30 days. About Enanta Pharmaceuticals, Inc. Enanta is using its robust

    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus Program at the 13th International RSV Symposium

    Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that an oral presentation and three posters, including one late breaker, highlighting the company's respiratory syncytial virus (RSV) program, will be presented at the 13th International RSV Symposium (RSV 2025) being held March 12-15 at Bourbon Cataratas do Iguazu, in Iguazu Falls, Brazil. Results from a Phase 2 human challenge study of EDP-323, an RSV L-protein inhibitor, which were announced in September 2024, will be highlighted in an oral presentation. Data from a Phase 2 study of zelicapavir, an N-protei

    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2024

    On Track to Report Topline Results for RSVHR, a Phase 2 Study of Zelicapavir in High-Risk Adults Infected with Respiratory Syncytial Virus (RSV), in 3Q 2025 Advancing Immunology Portfolio with Ongoing IND Enabling Studies of KIT Inhibitor EPS-1421 On Track to Announce STAT6 Development Candidate in 2H 2025 Operations Supported by Cash and Marketable Securities Totaling $216.7 Million at December 31, 2024, as well as Continuing Retained Royalties Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today reported financial results for its fiscal first quarter ended D

    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ENTA
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$ENTA
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$ENTA
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$ENTA
SEC Filings

See more

$ENTA
Leadership Updates

Live Leadership Updates

See more
  • Enanta Pharmaceuticals Announces the Appointment of Matthew P. Kowalsky as Chief Legal Officer

    Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced the appointment of Matthew P. Kowalsky, J.D., as Chief Legal Officer. In this role, he will lead all legal and compliance activities for Enanta, as well as provide strategic guidance and corporate governance oversight. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240430622885/en/Matthew P. Kowalsky, Chief Legal Officer, Enanta Pharmaceuticals, Inc. (Photo: Business Wire) "I'm pleased to welcome Matt to Enanta. The breadth of his legal expertise ac

    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Enanta Pharmaceuticals Appoints Scott T. Rottinghaus, M.D., as Senior Vice President and Chief Medical Officer

    Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and liver diseases, today announced the appointment of Scott T. Rottinghaus, M.D., as Senior Vice President and Chief Medical Officer, effective today, August 8, 2022. With over 20 years of experience in drug development across a broad range of therapeutic areas, Dr. Rottinghaus will lead the development, regulatory, clinical and medical functions in support of Enanta's pipeline. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220808005491/en/Scott T. Rottinghaus, M.D., Senior Vi

    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Enanta Pharmaceuticals Announces the Appointment of Brendan Luu as Senior Vice President, Business Development

    WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced the appointment of Brendan Luu as Senior Vice President, Business Development and member of the company’s senior management team. Mr. Luu brings more than 20 years of diversified business development and sales and marketing experience in the pharmaceutical and technology fields to Enanta, spanning a broad range of therapeutic areas, asset stages and deal structures. “It is an ideal time to welcome Brendan to the Enanta team, particularly as we prepare for a catalys

    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ENTA
Financials

Live finance-specific insights

See more
  • Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2024

    On Track to Report Topline Results for RSVHR, a Phase 2 Study of Zelicapavir in High-Risk Adults Infected with Respiratory Syncytial Virus (RSV), in 3Q 2025 Advancing Immunology Portfolio with Ongoing IND Enabling Studies of KIT Inhibitor EPS-1421 On Track to Announce STAT6 Development Candidate in 2H 2025 Operations Supported by Cash and Marketable Securities Totaling $216.7 Million at December 31, 2024, as well as Continuing Retained Royalties Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today reported financial results for its fiscal first quarter ended D

    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Enanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV)

    Observed an antiviral effect for the primary and secondary virology endpoints in the overall population, with a viral load decline of 1.4 log at the end of treatment in Part 2 Demonstrated a viral load decline of 1.2 log compared to placebo at the end of treatment in prespecified analysis of patients randomized within 3 days of symptom onset Zelicapavir was well-tolerated with a favorable safety profile Conference call and webcast to discuss data at 8:30 a.m. ET today Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced positive topline results from

    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Enanta Pharmaceuticals to Present Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for Respiratory Syncytial Virus (RSV)

    Conference call and webcast to discuss data on Monday, December 9 at 8:30 a.m. ET Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced the company will hold a conference call and webcast on Monday, December 9 at 8:30 a.m. ET to share topline results from RSVPEDs, a first-in-pediatrics Phase 2 study evaluating zelicapavir in hospitalized and non-hospitalized children aged 28 days to 36 months with respiratory syncytial virus (RSV). Conference Call and Webcast Information The live webcast on Monday, December 9 at 8:30 a.m. ET can be accessed at "Events & Pres

    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ENTA
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more